Enzalutamide

Enzalutamide 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy、Prostate Adenocarcinoma、Metastatic Castration-Resistant Prostate Cancer。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Enzalutamide 研究

• The COSMYC Trial (COmbined Suppression of MYC)

  II 期招募中美国NCT06922318

• A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

  III 期招募中美国澳大利亚Brazil加拿大NCT06136650

• ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

  II 期招募中美国中国NCT04986423

• A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

  III 期招募中美国Puerto RicoNCT07723248

• Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

  II 期招募中美国NCT05873192

• Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

  I 期 / II 期招募中美国NCT06236139

• A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

  I 期 / II 期招募中美国NCT06457919

• Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

  II 期招募中美国NCT06499870

• Study of ORIC-944 in Patients With Metastatic Prostate Cancer

  I 期招募中美国澳大利亚西班牙英国NCT05413421

• Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors

  III 期招募中丹麦法国西班牙NCT05974774

• ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

  III 期招募中比利时挪威瑞典瑞士NCT03903835

• A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

  I 期 / II 期招募中中国NCT07198633

• A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

  I 期招募中美国澳大利亚加拿大德国NCT07570979

• Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

  II 期招募中美国NCT06059118

• A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

  II 期招募中美国澳大利亚Brazil加拿大NCT07287150

• A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

  II 期招募中美国NCT06099769

• Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

  III 期招募中美国奥地利Brazil加拿大NCT07711002

• A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

  II 期招募中中国NCT07230106

• Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

  III 期招募中法国NCT06496581

• Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer

  III 期招募中英国NCT07751133

• A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

  I 期 / II 期招募中美国澳大利亚法国德国NCT07226986

• Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

  III 期招募中美国加拿大MexicoUruguayNCT06592924

• Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

  I 期 / II 期招募中美国NCT04946370

• Telmisartan in Prostate Cancer

  I 期招募中美国NCT06168487

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。